The ALK+ ALCL is the only PTCL subgroup with a relatively good prognosis [7], however, around 40% of ALK+ ALCL patients fail to be cured using standard therapeutic approaches [3]. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.